市場調查報告書

全球子宮內膜異位症治療藥市場分析與預測

Global Endometriosis Market Research and Forecast 2018-2023

出版商 Orion Market Research Pvt Ltd 商品編碼 658973
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
Back to Top
全球子宮內膜異位症治療藥市場分析與預測 Global Endometriosis Market Research and Forecast 2018-2023
出版日期: 2018年06月12日內容資訊: 英文
簡介

本報告提供全球子宮內膜異位症治療藥市場相關調查分析,提供市場概要,市場決策要素,市場區隔,競爭情形,各地區的分析,主要企業簡介等系統性資訊。

第1章 報告摘要

第2章 市場概要與考察

  • 定義
  • 分析師的見解·目前市場趨勢
  • 法規

第3章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 機會

第4章 市場區隔

  • 藥物類別
  • 診斷類別
  • 治療類別
  • 各銷售管道

第5章 競爭情形

  • 主要企業分析
  • 主要策略分析

第6章 各地區的分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

  • ABBOTT
  • ABBVIE INC.
  • ADDEX THERAPEUTICS
  • ALLERGAN
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA
  • BAYER AG
  • DEBIOPHARM GROUP
  • ELEXOPHARM
  • EVESTRA, INC.
  • FORENDO PHARMA
  • IPSEN
  • Kissei藥品工業
  • MEDITRINA PHARMACEUTICALS
  • MYOVANT SCIENCES LTD.
  • NEUROCRINE BIOSCIENCES, INC.
  • OBSEVA SA
  • OGEDA S.A.
  • ORPHAGEN PHARMACEUTICALS, INC.
  • PFIZER, INC.
  • PHILOGEN
  • REPROS THERAPEUTICS INC.
  • SANOFI
  • 武田藥品工業
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VALIRX
目錄
Product Code: OMR2018288

Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and periods lasting over 7 days, among others. Moreover, the impending treatment of endometriosis market may lead to infertility, formation of ovarian cysts, inflammation, and scar tissue and adhesion development, among others. According to endometriosis.org, the disorder affects an approximately of one in 10 women during their reproductive years, estimating to around 176 million women in the world.

Increasing female population of the reproductive age and growing awareness rate of the disease are some of the factors significantly contributing towards the growth of the global endometriosis market. High investment made by the government in the R&D of endometriosis disorder, so as to introduce enhanced medical treatment is fueling the market growth. Moreover, growing prevalence of endometriosis across the globe is leading to the expansion of product portfolio by major market players in the endometriosis market. However, high cost of advanced therapeutic drugs, high investment required for the R&D of novel drugs, and time required for the diagnosing of the disease are some of the factors hampering the growth of the global endometriosis market.

The endometriosis market can be segmented on the basis of drug type, diagnosis type, treatment type, and distribution channel. Based on drug type, the market is segmented into gonadotropins releasing hormone agonists, non-steroidal anti-inflammatory drugs, progestin, and oral contraceptive pills. Based on diagnosis type, the market is bifurcated into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography. Based on treatment type, the market is segmented into hormonal therapy and pain management. Based on distribution channel, the market is diversified into hospital pharmacies, drug stores, retail pharmacies, mail order pharmacies, and e-commerce.

The global endometriosis market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global endometriosis market and is expected to retain its position over the forecast period. This is mainly owing to large number of female population suffering from endometriosis in the region. Moreover, increasing spending on R&D by the government in the treatment of endometriosis and endometrial cancer is another factor fueling growth of the endometriosis market in the region.

Some of the key vendors of the endometriosis market are Abbott, AbbVie Inc., Bayer AG, Ipsen, Myovant Sciences Ltd., Pfizer, Inc., Philogen, Astellas Pharma, Orphagen Pharmaceuticals, Inc., and Meditrina Pharmaceuticals, among others. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development and so on. For instance, in March 2018, Astellas Pharma announced the development of Opigolix (ASP 1707), a luteinizing-hormone-releasing hormone receptor antagonist. The product can be used for the oral treatment of endometriosis.

Research Methodology:

The market study of endometriosis market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Authentic Public Databases such as WHO, endometriosis.org, womenshealth.gov, and the National Center for Biotechnology Information, among others.
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalogue.
  • Supplier Websites such as Alibaba, amazon for pricing analysis.

The report is intended for endometriosis drug manufacturers, healthcare provider, government organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms, and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.

Market Segmentation:

Global endometriosis market is segmented on the basis of regional outlook and following segments:

1. Global Endometriosis Market Research and Analysis, By Drug Type

2. Global Endometriosis Market Research and Analysis, By Diagnosis Type

3. Global Endometriosis Market Research and Analysis, By Treatment Type

4. Global Endometriosis Market Research and Analysis, By Distribution Channel

5. Global Endometriosis Market Research and Analysis, By Region

THE REPORT COVERS:

  • Comprehensive research methodology of Global Endometriosis Market.
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Endometriosis Market.
  • Insights about market determinants which are stimulating the Global Endometriosis Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

CHAPTER 1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

CHAPTER 2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
      • 2.3.1.1. UNITED STATES
      • 2.3.1.2. EUROPEAN UNION
      • 2.3.1.3. CHINA
      • 2.3.1.4. INDIA

CHAPTER 3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. AVAILABILITY OF ENHANCED MEDICATIONS
    • 3.1.2. GROWING GERIATRIC POPULATION
    • 3.1.3. GROWING AWARENESS RATE OF THE DISEASE
    • 3.1.4. INCREASING GOVERNMENT FUNDINGS FOR TREATMENT OF ENDOMETRIOSIS
  • 3.2. RESTRAINTS
    • 3.2.1. MORE TIME REQUIRED FOR THE DIAGNOSIS
    • 3.2.2. HIGH COST OF DRUGS
    • 3.2.3. HIGH R&D EXPENDITURE
  • 3.3. OPPORTUNITIES
    • 3.3.1. INCREASING DEMAND FOR MINIMALLY INVASIVE TREATMENT
    • 3.3.2. EMERGING TREATMENT FOR ENDOMETRIOSIS & ENDOMETRIAL CANCER

CHAPTER 4. MARKET SEGMENTATION

  • 4.1. GLOBAL ENDOMETRIOSIS MARKET, BY DRUG TYPE
    • 4.1.1. GONADOTROPINS RELEASING HORMONE AGONISTS
    • 4.1.2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    • 4.1.3. PROGESTIN
    • 4.1.4. ORAL CONTRACEPTIVE PILLS
  • 4.2. GLOBAL ENDOMETRIOSIS MARKET, BY DIAGNOSIS TYPE
    • 4.2.1. ULTRASOUND
    • 4.2.2. PELVIC EXAM
    • 4.2.3. LAPAROSCOPY
    • 4.2.4. MAGNETIC RESONANCE IMAGING (MRI)
    • 4.2.5. HYSTEROSCOPY
    • 4.2.6. SONOHYSTEROGRAPHY
  • 4.3. GLOBAL ENDOMETRIOSIS MARKET, BY TREATMENT TYPE
    • 4.3.1. HORMONAL THERAPY
    • 4.3.2. PAIN MANAGEMENT
  • 4.4. GLOBAL ENDOMETRIOSIS MARKET BY DISTRIBUTION CHANNEL
    • 4.4.1. HOSPITAL PHARMACIES
    • 4.4.2. DRUG STORES
    • 4.4.3. RETAIL PHARMACIES
    • 4.4.4. MAIL ORDER PHARMACIES
    • 4.4.5. E-COMMERCE

CHAPTER 5. COMPETITIVE LANDSCAPE

  • 5.1. KEY COMPANY ANALYSIS
  • 5.2. KEY STRATEGY ANALYSIS

CHAPTER 6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICAN
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. U.K
    • 6.2.2. GERMANY
    • 6.2.3. ITALY
    • 6.2.4. SPAIN
    • 6.2.5. FRANCE
    • 6.2.6. ROE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
    • 6.3.4. ROAPAC
  • 6.4. REST OF THE WORLD

CHAPTER 7. COMPANY PROFILES

  • 7.1. ABBOTT
  • 7.2. ABBVIE INC.
  • 7.3. ADDEX THERAPEUTICS
  • 7.4. ALLERGAN
  • 7.5. ASTELLAS PHARMA INC.
  • 7.6. ASTRAZENECA
  • 7.7. BAYER AG
  • 7.8. DEBIOPHARM GROUP
  • 7.9. ELEXOPHARM
  • 7.10. EVESTRA, INC.
  • 7.11. FORENDO PHARMA
  • 7.12. IPSEN
  • 7.13. KISSEI PHARMACEUTICAL CO., LTD.
  • 7.14. MEDITRINA PHARMACEUTICALS
  • 7.15. MYOVANT SCIENCES LTD.
  • 7.16. NEUROCRINE BIOSCIENCES, INC.
  • 7.17. OBSEVA SA
  • 7.18. OGEDA S.A.
  • 7.19. ORPHAGEN PHARMACEUTICALS, INC.
  • 7.20. PFIZER, INC.
  • 7.21. PHILOGEN
  • 7.22. REPROS THERAPEUTICS INC.
  • 7.23. SANOFI
  • 7.24. TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 7.25. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 7.26. VALIRX

List of Tables

  • TABLE # 1 GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL GONADOTROPINS RELEASING HORMONE AGONISTS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL PROGESTIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL ORAL CONTRACEPTIVE PILLS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL ULTRASOUND MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL PELVIC EXAM MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL LAPAROSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL HYSTEROSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL SONOHYSTEROGRAPHY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL HORMONAL THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL PAIN MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 16 GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 17 GLOBAL HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 18 GLOBAL DRUG STORES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 19 GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 20 GLOBAL MAIL ORDER PHARMACIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 21 GLOBAL E-COMMERCE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 22 GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
  • TABLE # 23 NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 24 NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2017-2023 ($ MILLION)
  • TABLE # 25 NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2017-2023 ($ MILLION)
  • TABLE # 26 NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2017-2023 ($ MILLION)
  • TABLE # 27 NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 28 EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 29 EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2017-2023 ($ MILLION)
  • TABLE # 30 EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2017-2023 ($ MILLION)
  • TABLE # 31 EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2017-2023 ($ MILLION)
  • TABLE # 32 EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 33 APAC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 34 APAC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2017-2023 ($ MILLION)
  • TABLE # 35 APAC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2017-2023 ($ MILLION)
  • TABLE # 36 APAC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2017-2023 ($ MILLION)
  • TABLE # 37 APAC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 38 ROW ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2017-2023 ($ MILLION)
  • TABLE # 39 ROW ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2017-2023 ($ MILLION)
  • TABLE # 40 ROW ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2017-2023 ($ MILLION)
  • TABLE # 41 ROW ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL ENDOMETRIOSIS MARKET SHARE BY DRUG TYPE, 2017 VS 2023 (%)
  • FIGURE # 2 GLOBAL ENDOMETRIOSIS MARKET SHARE BY DIAGNOSIS TYPE, 2017 VS 2023 (%)
  • FIGURE # 3 GLOBAL ENDOMETRIOSIS MARKET SHARE BY TREATMENT TYPE, 2017 VS 2023 (%)
  • FIGURE # 4 GLOBAL ENDOMETRIOSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2017 VS 2023 (%)
  • FIGURE # 5 US ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 CANADA ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 UK ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 FRANCE ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 GERMANY ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 ITALY ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 11 SPAIN ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 12 ROE ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 13 INDIA ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 14 CHINA ENDOMETRIOSIS MARKETSIZE, 2017-2023 ($ MILLION)
  • FIGURE # 15 JAPAN ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 16 ROAPAC ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 17 REST OF THE WORLD ENDOMETRIOSIS MARKET SIZE, 2017-2023 ($ MILLION)
Back to Top